Document Detail

Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
MedLine Citation:
PMID:  16908348     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Drugs such as cetuximab or erlotinib, which inhibit the epidermal growth factor receptor, are increasingly being used in treatment of solid tumors. This has led to the appearance of new secondary effects.
OBJECTIVE: We sought to describe the cutaneous side effects and their management in patients with cancer treated with cetuximab or erlotinib.
METHODS: We clinically examined 30 patients determining type, frequency, treatment, and evolution of side effects.
RESULTS: Most patients presented with a cutaneous reaction consisting of a follicular eruption, typically appearing in seborrheic areas within the first 15 days of treatment. Painful fissures in palms and soles and paronychia were the second most common cutaneous toxicities. We also noticed an alteration in hair growth at several months' follow-up. As these secondary effects responded well to treatment, few patients discontinued the antineoplastic therapy because of cutaneous toxicity.
LIMITATIONS: This was a prospective but uncontrolled study.
CONCLUSION: Although these new targeted therapies have low systemic toxicity because of their high specificity, cutaneous side effects are common and may be serious.
Esther Roé; María Pilar García Muret; Eugenio Marcuello; Jaume Capdevila; Cinta Pallarés; Agustín Alomar
Related Documents :
20479298 - Morphologic features and natural history of scalp nevi in children.
20670088 - Hyposensitization in the treatment of resistant cases of vernal keratoconjunctivitis.
12873868 - Nonablative laser resurfacing using the long-pulse (1064-nm) nd:yag laser.
21880278 - A randomized controlled trial of nuvaring versus combined oral contraceptive pills for ...
12479908 - Vascular brachytherapy after percutaneous transluminal angioplasty of superficial femor...
16538688 - Safety and efficacy of staple-mediated femoral arteriotomy closure: results from a rand...
Publication Detail:
Type:  Journal Article     Date:  2006-07-13
Journal Detail:
Title:  Journal of the American Academy of Dermatology     Volume:  55     ISSN:  1097-6787     ISO Abbreviation:  J. Am. Acad. Dermatol.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-15     Completed Date:  2006-09-12     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  7907132     Medline TA:  J Am Acad Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  429-37     Citation Subset:  IM    
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects*,  therapeutic use
Antineoplastic Agents / adverse effects*,  therapeutic use
Drug Eruptions / drug therapy*,  pathology
Middle Aged
Neoplasms / drug therapy*
Prospective Studies
Protein Kinase Inhibitors / adverse effects*,  therapeutic use
Quinazolines / adverse effects*,  therapeutic use
Receptor, Epidermal Growth Factor / antagonists & inhibitors
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Protein Kinase Inhibitors; 0/Quinazolines; EC, Epidermal Growth Factor; J4T82NDH7E/erlotinib; PQX0D8J21J/cetuximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical and histopathologic characteristics of nevus depigmentosus.
Next Document:  Alopecia areata: a long term follow-up study of 191 patients.